Mitochondrial encephalomyopathies (MEs) result from mutations in mitochondrial genes critical to oxidative phosphorylation. Severe and untreatable ME results from mutations affecting each endogenous mitochondrial encoded gene, including all 13 established protein coding genes. Effective techniques to manipulate mitochondrial genome are limited and targeted mitochondrial protein expression is currently unavailable. Here we report the development of a mitochondrial-targeted RNA expression (mtTRES) vector capable of protein expression within mitochondria (mtTRES Pro ). We demonstrate that mtTRES Pro expressed RNAs are targeted to mitochondria and are capable of being translated using EGFP encoded constructs in vivo. We additionally test mtTRES Pro constructs encoding wild type ATP6 for their ability to rescue an established ATP6 1 Drosophila model of ME.
Mitochondrial encephalomyopathies (MEs) result from mutations in mitochondrial genes critical to oxidative phosphorylation. Severe and untreatable ME results from mutations affecting each endogenous mitochondrial encoded gene, including all 13 established protein coding genes. Effective techniques to manipulate mitochondrial genome are limited and targeted mitochondrial protein expression is currently unavailable. Here we report the development of a mitochondrial-targeted RNA expression (mtTRES) vector capable of protein expression within mitochondria (mtTRES Genetic rescue is examined including tests with co-expression of mitochondrial targeted translational inhibitors TLI-NCL::ATP6 RNAs that function to reduce expression of the endogenous mutant protein. The data demonstrate allotopic RNA expression of mitochondrial targeted wild type ATP6 coding RNAs are sufficient to partially rescue a severe and established animal model of ME but only when combined with a method to inhibit mutant protein expression, which likely competes for incorporation into complex V.
Introduction
Numerous primary respiratory diseases known as mitochondrial encephalomyopathies (ME) are caused by mutations in mitochondrial DNA (mtDNA). Among the most severe MEs are those resulting from mutations directly affecting the mitochondrial DNA. There does not exist an efficacious treatment for mitochondrial disease and the development of a gene therapy approach would have a tremendous impact on patients. Gene therapies for ME patients are complicated by the fact that all established gene transfer methods introduce genes into the nucleus and there is no known method to introduce genes into mitochondria, although efforts to do so are actively being pursued (Niazi et al., 2012) . Several groups have proposed mitochondrial-targeted protein-based gene therapies known as allotopic protein expression, however the available data remain somewhat controversial (Bietenhader et al., 2012; Bokori-Brown and Holt, 2006; Bonnet et al., 2008; Dunn and Pinkert, 2012; Ellouze et al., 2008; Figueroa-Martinez et al., 2010; Gray et al., 1996; Guy et al., 2009; Guy et al., 2002; Manfredi et al., 2002; Mukhopadhyay et al., 2006; Oca-Cossio et al., 2003) . Expression of hydrophobic mitochondrial proteins within the cytosol could result in aggregation toxicity and it is not known whether such proteins would be efficiently imported or assembled into mature complexes. Current allotopic expression approaches do not address an inherent issue of competition by endogenous mutant proteins. Mitochondrial oxidative phosphorylation complexes are assembled from numerous protein subunits encoded by the mitochondrial as well as the nuclear genomes. Thus, allotopically expressed mitochondrial proteins will typically need to compete with mutant protein when assembling into a functional complex: a complication that has yet to be addressed.
Previously, we described a method to knock down mitochondrialencoded proteins using mitochondrial targeted small chimeric RNAs that function as translational inhibitors (TLI) (Towheed et al., 2014) . These small chimeric RNAs expressed from mtTRES vectors have a complementary region designed to interfere with mitochondrial translation initiation of a target gene and are able to specifically knock down protein levels in human cells and in vivo. Exploiting the endogenous RNA import pathway we sought to circumvent the technical hurdles associated with allotopic protein expression and asked whether we 
